Hanmi Pharmaceutical Q2 Operating Profit Doubles to 124.1 Billion Won, Boosted by Lilly Upfront Payment
According to Yonhapinfomax consensus, Hanmi Pharmaceutical is expected to report second-quarter operating profit of 124.1 billion won on July 15, surging 105.46% year-over-year. The sharp increase is primarily driven by a 112.9 billion won upfront payment from Eli Lilly for technology licensing of s
Hanmi Pharmaceutical3.35%
GateNews·07-14 23:58
